<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575404</url>
  </required_header>
  <id_info>
    <org_study_id>15-166</org_study_id>
    <nct_id>NCT02575404</nct_id>
  </id_info>
  <brief_title>GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients</brief_title>
  <official_title>Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galectin Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Providence Health &amp; Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of&#xD;
      pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and&#xD;
      neck squamous cell cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will employ a 3+3 phase I design with dose escalation of GR-MD-02 in conjunction&#xD;
      with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma who&#xD;
      have had progression after ipilimumab and/or BRAF targeted therapy when a BRAF mutation is&#xD;
      present, non-small cell lung cancer patients with disease progression after targeted therapy,&#xD;
      or head and neck squamous cell carcinoma patients with disease progression after at least one&#xD;
      platinum-containing regimen.&#xD;
&#xD;
      In addition to monitoring for toxicity and clinical response, blood and tumor samples will be&#xD;
      obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell&#xD;
      checkpoint inhibition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 16, 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and Severity of Treatment-Related Adverse Events Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</measure>
    <time_frame>85 Days</time_frame>
    <description>Patients are seen in clinic 7 times over 85 days. At each visit, a research nurse performs a toxicity check. Patients have 5 physical exams during the 85-day period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the response rate to combined therapy with GR-MD-02 and pembrolizumab in patients.</measure>
    <time_frame>Baseline and at Day 85</time_frame>
    <description>Patients will have PET and CT scans at baseline and after 85 days to assess response to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the biological activity of GR-MD-02 in combination with pembrolizumab.</measure>
    <time_frame>85 Days</time_frame>
    <description>Patients will provide 5 blood samples over 85 days to measure the absolute number of CD4+T Cells, CD8+ T cells and melanoma-specific T cells</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>2 mg/kg GR-MD-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg/kg GR-MD-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg/kg GR-MD-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GR-MD-02</intervention_name>
    <description>Patients will receive five doses of GR-MD-02 intravenously over 85 Days.</description>
    <arm_group_label>2 mg/kg GR-MD-02</arm_group_label>
    <arm_group_label>4 mg/kg GR-MD-02</arm_group_label>
    <arm_group_label>8 mg/kg GR-MD-02</arm_group_label>
    <other_name>Galactoarabino-rhamnogalactouronate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.</description>
    <arm_group_label>2 mg/kg GR-MD-02</arm_group_label>
    <arm_group_label>4 mg/kg GR-MD-02</arm_group_label>
    <arm_group_label>8 mg/kg GR-MD-02</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with metastatic or unresectable melanoma for whom treatment with&#xD;
             pembrolizumab is indicated. Histological confirmation of melanoma will be required by&#xD;
             previous biopsy or cytology.&#xD;
&#xD;
          -  Patients with non-small cell lung cancer for whom treatment with pembrolizumab is&#xD;
             indicated.&#xD;
&#xD;
          -  Patients with squamous cell carcinoma of the head and neck for whom treatment with&#xD;
             pembrolizumab is indicated&#xD;
&#xD;
          -  Patients who have radiographic progression using Response Evaluation Criteria In Solid&#xD;
             Tumors (RECIST) currently on pembrolizumab are also eligible.&#xD;
&#xD;
          -  Patients must be â‰¥ 18 years of age.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.&#xD;
&#xD;
          -  Women of childbearing potential must have a serum or urine pregnancy test performed&#xD;
             within 72 hours prior to the start of protocol treatment. The results of this test&#xD;
             must be negative in order for the patient to be eligible. In addition, women of&#xD;
             childbearing potential as well as male patients must agree to take appropriate&#xD;
             precautions to avoid pregnancy.&#xD;
&#xD;
          -  No active bleeding.&#xD;
&#xD;
          -  Anticipated lifespan greater than 12 weeks.&#xD;
&#xD;
          -  Patients must sign a study-specific consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously received a galectin antagonist&#xD;
&#xD;
          -  Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo&#xD;
&#xD;
          -  Patients with history of colitis&#xD;
&#xD;
          -  Patients with untreated brain metastases. Patients with treated brain metastases who&#xD;
             demonstrate control of brain metastases with follow-up imaging 4 or more weeks after&#xD;
             initial therapy are eligible.&#xD;
&#xD;
          -  Other active metastatic cancer requiring treatment.&#xD;
&#xD;
          -  Patients with active infection requiring antibiotics.&#xD;
&#xD;
          -  Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo&#xD;
             or fetus.&#xD;
&#xD;
          -  Need for chronic steroids. Inhaled corticosteroids are acceptable.&#xD;
&#xD;
          -  Laboratory values (to be performed within 28 days of enrollment) outside of&#xD;
             protocol-specified ranges.&#xD;
&#xD;
          -  Inability to give informed consent and comply with the protocol. Patients with a&#xD;
             history of psychiatric illness must be judged able to understand fully the&#xD;
             investigational nature of the study and the risks associated with the therapy.&#xD;
&#xD;
          -  Any medical condition that in the opinion of the Principal Investigator would&#xD;
             compromise the safety or conduct of the study procedures.&#xD;
&#xD;
          -  Unresolved immune-mediated pneumonitis, diarrhea, elevation of hepatocellular enzymes&#xD;
             or other toxicities requiring greater than physiological replacement doses of&#xD;
             steroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Curti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://oregon.providence.org/our-services/p/providence-cancer-center/</url>
    <description>Providence Cancer Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Keytruda</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>GR-MD-02</keyword>
  <keyword>Galactoarabino-rhamnogalacturonate</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

